Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | PRKDC | P78527 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18207851 | 1.00 | IRAK4 (0.47) | IRAK4ABL1ITGALSCDPRKDC | |
| SCHEMBL3436255 | 0.91 | IRAK4 (0.41) | IRAK4ABL1ITGALKDM4EUSP2 | |
| SCHEMBL13162582 | 0.88 | IRAK4 (0.36) | IRAK4ITGALKDM4E | |
| SCHEMBL13162580 | 0.85 | IRAK4 (0.38) | IRAK4ITGALKDM4EUSP2HPGD | |
| SCHEMBL17383754 | 0.84 | USP2 (0.40) | IRAK4ITGALKDM4EUSP2HPGD | |
| SCHEMBL13162584 | 0.83 | IRAK4 (0.36) | IRAK4ITGALKDM4EUSP2HPGD | |
| SCHEMBL13162585 | 0.82 | IRAK4 (0.37) | IRAK4ITGALKDM4EUSP2HPGD | |
| SCHEMBL2770990 | 0.81 | HCRTR1 (0.46) | IRAK4KDM4E | |
| SCHEMBL28710578 | 0.81 | HCRTR1 (0.46) | IRAK4KDM4E | |
| SCHEMBL13634332 | 0.81 | SCD5 (0.39) | IRAK4SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2024-05-14 | — | — | US | disclosed |
| EP-4353324-A2 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-04-17 | — | — | EP | disclosed |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-10-19 | — | — | US | disclosed |
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-04 | — | — | US | disclosed |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-02-24 | — | — | US | disclosed |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-05-04 | — | — | US | disclosed |
| EP-3805233-A1 | (R) AND (S) ENANTIOMER OF N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOLE-CARBOXAMIDE AS IRAK4 INHIBITORS FOR TREATING CANCER AND INFLAMMATORY DISEASES | Aurigene Discovery Technologies Limited (IN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3466955-B1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | AURIGENE DISCOVERY TECH LTD (IN) | 2020-12-16 | — | — | EP | disclosed |
| CN-111362966-A | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-20200190112-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2020-06-18 | — | — | US | disclosed |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-06-01 | — | — | US | disclosed |
| EP-3157521-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-04-26 | — | — | EP | disclosed |
| WO-2017009798-A1 | INDAZOLE AND AZAINDAZOLE COMPOUNDS AS IRAK-4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-01-19 | — | — | WO | disclosed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | disclosed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015193846-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691987-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 952/4885ITGAL 4028/4885 |
| US-20200190112-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 952/4885ITGAL 4028/4885 |
| US-11981685-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 897/4885ITGAL 3702/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885ABL1 617/4885ITGAL 3703/4885 |
| US-20220056046-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 952/4885ITGAL 4028/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 547/4885ITGAL 2612/4885 |
| US-20230331740-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 897/4885ITGAL 3702/4885 |
| US-10995100-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885ABL1 952/4885ITGAL 4028/4885 |
| US-20170152263-A1 | Substituted Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK2 | IRAK4 1/4885ABL1 171/4885ITGAL 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.